Extensive Gene Amplification as a Mechanism for Piperacillin-Tazobactam Resistance in Escherichia coli

ABSTRACT Although the TEM-1 β-lactamase (BlaTEM-1) hydrolyzes penicillins and narrow-spectrum cephalosporins, organisms expressing this enzyme are typically susceptible to β-lactam/β-lactamase inhibitor combinations such as piperacillin-tazobactam (TZP). However, our previous work led to the discovery of 28 clinical isolates of Escherichia coli resistant to TZP that contained only blaTEM-1. One of these isolates, E. coli 907355, was investigated further in this study. E. coli 907355 exhibited significantly higher β-lactamase activity and BlaTEM-1 protein levels when grown in the presence of subinhibitory concentrations of TZP. A corresponding TZP-dependent increase in blaTEM-1 copy number was also observed, with as many as 113 copies of the gene detected per cell. These results suggest that TZP treatment promotes an increase in blaTEM-1 gene dosage, allowing BlaTEM-1 to reach high enough levels to overcome inactivation by the available tazobactam in the culture. To better understand the nature of the blaTEM-1 copy number proliferation, whole-genome sequence (WGS) analysis was performed on E. coli 907355 in the absence and presence of TZP. The WGS data revealed that the blaTEM-1 gene is located in a 10-kb genomic resistance module (GRM) that contains multiple resistance genes and mobile genetic elements. The GRM was found to be tandemly repeated at least 5 times within a p1ESCUM/p1ECUMN-like plasmid when bacteria were grown in the presence of TZP. IMPORTANCE Understanding how bacteria acquire resistance to antibiotics is essential for treating infected patients effectively, as well as preventing the spread of resistant organisms. In this study, a clinical isolate of E. coli was identified that dedicated more than 15% of its genome toward tandem amplification of a ~10-kb resistance module, allowing it to escape antibiotic-mediated killing. Our research is significant in that it provides one possible explanation for clinical isolates that exhibit discordant behavior when tested for antibiotic resistance by different phenotypic methods. Our research also shows that GRM amplification is difficult to detect by short-read WGS technologies. Analysis of raw long-read sequence data was required to confirm GRM amplification as a mechanism of antibiotic resistance. Understanding how bacteria acquire resistance to antibiotics is essential for treating infected patients effectively, as well as preventing the spread of resistant organisms. In this study, a clinical isolate of E. coli was identified that dedicated more than 15% of its genome toward tandem amplification of a ~10-kb resistance module, allowing it to escape antibiotic-mediated killing. Our research is significant in that it provides one possible explanation for clinical isolates that exhibit discordant behavior when tested for antibiotic resistance by different phenotypic methods. Our research also shows that GRM amplification is difficult to detect by short-read WGS technologies. Analysis of raw long-read sequence data was required to confirm GRM amplification as a mechanism of antibiotic resistance.

[1]  David E Greenberg,et al.  Whole-Genome Sequencing Accurately Identifies Resistance to Extended-Spectrum &bgr;-Lactams for Major Gram-Negative Bacterial Pathogens , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  M. Watson,et al.  Tandem Amplification of the Staphylococcal Cassette Chromosome mec Element Can Drive High-Level Methicillin Resistance in Methicillin-Resistant Staphylococcus aureus , 2017, Antimicrobial Agents and Chemotherapy.

[3]  D. Nicolau,et al.  In Vitro-In Vivo Discordance with Humanized Piperacillin-Tazobactam Exposures against Piperacillin-Tazobactam-Resistant/Pan-β-Lactam-Susceptible Klebsiella pneumoniae Strains , 2017, Antimicrobial Agents and Chemotherapy.

[4]  T. Naas,et al.  Chromosomal Amplification of the blaOXA-58 Carbapenemase Gene in a Proteus mirabilis Clinical Isolate , 2016, Antimicrobial Agents and Chemotherapy.

[5]  Danna R. Gifford,et al.  Multicopy plasmids potentiate the evolution of antibiotic resistance in bacteria , 2016, Nature Ecology &Evolution.

[6]  D. Nicolau,et al.  In Vitro-In Vivo Discordance with Humanized Piperacillin-Tazobactam Exposures against Piperacillin-Tazobactam-Resistant/Pan-β-Lactam-Susceptible Escherichia coli , 2016, Antimicrobial Agents and Chemotherapy.

[7]  A. Birgy,et al.  Genome Analysis of Kingella kingae Strain KWG1 Reveals How a β-Lactamase Gene Inserted in the Chromosome of This Species , 2015, Antimicrobial Agents and Chemotherapy.

[8]  Hiroshi Nikaido,et al.  The Challenge of Efflux-Mediated Antibiotic Resistance in Gram-Negative Bacteria , 2015, Clinical Microbiology Reviews.

[9]  Aaron R. Quinlan,et al.  Poretools: a toolkit for analyzing nanopore sequence data , 2014, bioRxiv.

[10]  Torsten Seemann,et al.  Prokka: rapid prokaryotic genome annotation , 2014, Bioinform..

[11]  Robert J. Clifford,et al.  Amplification of Aminoglycoside Resistance Gene aphA1 in Acinetobacter baumannii Results in Tobramycin Therapy Failure , 2014, mBio.

[12]  A. van Belkum,et al.  Population Analysis of Escherichia coli Isolates with Discordant Resistance Levels by Piperacillin-Tazobactam Broth Microdilution and Agar Dilution Testing , 2013, Antimicrobial Agents and Chemotherapy.

[13]  W. Dunne,et al.  International dissemination of Escherichia coli strains with discrepant behaviour in phenotypic antimicrobial susceptibility tests , 2013, European Journal of Clinical Microbiology & Infectious Diseases.

[14]  Sergey I. Nikolenko,et al.  SPAdes: A New Genome Assembly Algorithm and Its Applications to Single-Cell Sequencing , 2012, J. Comput. Biol..

[15]  N. Woodford,et al.  False extended-spectrum {beta}-lactamase phenotype in clinical isolates of Escherichia coli associated with increased expression of OXA-1 or TEM-1 penicillinases and loss of porins. , 2011, The Journal of antimicrobial chemotherapy.

[16]  D. Paterson,et al.  Clinical Characteristics of Bloodstream Infections Due to Ampicillin-Sulbactam-Resistant, Non-Extended- Spectrum-β-Lactamase-Producing Escherichia coli and the Role of TEM-1 Hyperproduction , 2010, Antimicrobial Agents and Chemotherapy.

[17]  R. Bonomo,et al.  Three Decades of β-Lactamase Inhibitors , 2010, Clinical Microbiology Reviews.

[18]  G. Jacoby,et al.  Updated Functional Classification of β-Lactamases , 2009, Antimicrobial Agents and Chemotherapy.

[19]  O. Berg,et al.  Contribution of Gene Amplification to Evolution of Increased Antibiotic Resistance in Salmonella typhimurium , 2009, Genetics.

[20]  Linus Sandegren,et al.  Bacterial gene amplification: implications for the evolution of antibiotic resistance , 2009, Nature Reviews Microbiology.

[21]  Gonçalo R. Abecasis,et al.  The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..

[22]  Richard Durbin,et al.  Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .

[23]  M. Touchon,et al.  A Module Located at a Chromosomal Integration Hot Spot Is Responsible for the Multidrug Resistance of a Reference Strain from Escherichia coli Clonal Group A , 2009, Antimicrobial Agents and Chemotherapy.

[24]  A. Danchin,et al.  Organised Genome Dynamics in the Escherichia coli Species Results in Highly Diverse Adaptive Paths , 2009, PLoS genetics.

[25]  Jaai Kim,et al.  Absolute and relative QPCR quantification of plasmid copy number in Escherichia coli. , 2006, Journal of biotechnology.

[26]  W. Kern,et al.  Effect of 1-(1-naphthylmethyl)-piperazine, a novel putative efflux pump inhibitor, on antimicrobial drug susceptibility in clinical isolates of Escherichia coli. , 2006, The Journal of antimicrobial chemotherapy.

[27]  M. Pérez-Moreno,et al.  Mechanisms of reduced susceptibility to amoxycillin-clavulanic acid in Escherichia coli strains from the health region of Tortosa (Catalonia, Spain). , 2004, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[28]  E. Nelson,et al.  Outer membrane protein alterations and blaTEM-1 variants: their role in beta-lactam resistance in Klebsiella pneumoniae. , 2003, The Journal of antimicrobial chemotherapy.

[29]  P. Nordmann,et al.  Promoters P3, Pa/Pb, P4, and P5 Upstream from blaTEM Genes and Their Relationship to β-Lactam Resistance , 2002, Antimicrobial Agents and Chemotherapy.

[30]  Ludmil Benov,et al.  Disrupting Escherichia coli: a comparison of methods. , 2002, Journal of biochemistry and molecular biology.

[31]  Angela Lee,et al.  Identification and Characterization of Inhibitors of Multidrug Resistance Efflux Pumps in Pseudomonas aeruginosa: Novel Agents for Combination Therapy , 2001, Antimicrobial Agents and Chemotherapy.

[32]  T. Renau,et al.  Inhibitors of efflux pumps in Pseudomonas aeruginosa potentiate the activity of the fluoroquinolone antibacterial levofloxacin. , 1999, Journal of medicinal chemistry.

[33]  I. Phillips,et al.  Mechanisms of hyperproduction of TEM-1 beta-lactamase by clinical isolates of Escherichia coli. , 1995, The Journal of antimicrobial chemotherapy.

[34]  I. Phillips,et al.  Incidence and mechanisms of resistance to the combination of amoxicillin and clavulanic acid in Escherichia coli , 1995, Antimicrobial agents and chemotherapy.

[35]  G. Jacoby,et al.  A functional classification scheme for beta-lactamases and its correlation with molecular structure , 1995, Antimicrobial agents and chemotherapy.

[36]  I. Phillips,et al.  Effect of hyperproduction of TEM-1 beta-lactamase on in vitro susceptibility of Escherichia coli to beta-lactam antibiotics , 1994, Antimicrobial Agents and Chemotherapy.

[37]  D. Livermore,et al.  Susceptibility of Escherichia coli isolates with TEM-1 beta-lactamase to combinations of BRL42715, tazobactam or clavulanate with piperacillin or amoxycillin . , 1991, The Journal of antimicrobial chemotherapy.

[38]  D. Livermore,et al.  Activity of clavulanate combinations against TEM-1 beta-lactamase-producing Escherichia coli isolates obtained in 1982 and 1989. , 1991, The Journal of antimicrobial chemotherapy.

[39]  F. Baquero,et al.  Factors determining resistance to β-lactam combined with β-lactamase inhibitors in Escherichia coli , 1991 .

[40]  R. Wallace,,et al.  Acquired resistance of Nocardia brasiliensis to clavulanic acid related to a change in beta-lactamase following therapy with amoxicillin-clavulanic acid , 1991, Antimicrobial Agents and Chemotherapy.

[41]  E. Myers,et al.  Basic local alignment search tool. , 1990, Journal of molecular biology.

[42]  I. Phillips,et al.  Hyperproduction of TEM-1 beta-lactamase in clinical isolates of Escherichia coli serotype O15. , 1990, FEMS microbiology letters.

[43]  F. Baquero,et al.  Small plasmids are involved in amoxicillin-clavulanate resistance in Escherichia coli , 1989, Antimicrobial Agents and Chemotherapy.

[44]  G. Samonis,et al.  Resistance to ticarcillin-potassium clavulanate among clinical isolates of the family Enterobacteriaceae: role of PSE-1 beta-lactamase and high levels of TEM-1 and SHV-1 and problems with false susceptibility in disk diffusion tests , 1988, Antimicrobial Agents and Chemotherapy.

[45]  F. Baquero,et al.  RESISTANCE TO BETA-LACTAM/CLAVULANATE , 1987, The Lancet.

[46]  R. Ambler,et al.  The structure of beta-lactamases. , 1980, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[47]  S. Falkow,et al.  Origin of the TEM-beta-lactamase gene found on plasmids , 1975, Journal of bacteriology.

[48]  N. Datta,et al.  Penicillinase Synthesis Controlled By Infectious R Factors In Enterobacteriaceae , 1965, Nature.

[49]  R. Bonomo β-Lactamases: A Focus on Current Challenges. , 2017, Cold Spring Harbor perspectives in medicine.

[50]  Vanessa Hertzog,et al.  Pcr Protocols A Guide To Methods And Applications , 2016 .

[51]  N. Yuxin Hyperproduction of TEM-1 β-lactamase mediates the resistance of Escherichia coli to piperacillin-tazobactam and cefoperazone , 2013 .

[52]  M. Ferraro Performance standards for antimicrobial susceptibility testing , 2001 .

[53]  Mary Jane Ferraro,et al.  Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : approved standard , 2000 .

[54]  N. Willetts Structure and function of the F factor and mechanism of conjugation , 1987 .